Klotho Neurosciences, Inc. (NASDAQ:KLTO) — Market Cap & Net Worth
Market Cap & Net Worth: Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. (NASDAQ:KLTO) has a market capitalization of $50.59 Million ($50.59 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21925 globally and #4819 in its home market, demonstrating a 13.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Klotho Neurosciences, Inc.'s stock price $0.47 by its total outstanding shares 108088661 (108.09 Million). Review KLTO total debt and obligations to assess the company's total debt and financial obligations.
Klotho Neurosciences, Inc. Market Cap History: 2022 to 2026
Klotho Neurosciences, Inc.'s market capitalization history from 2022 to 2026. Data shows change from $1.09 Billion to $50.59 Million (-54.53% CAGR).
Index Memberships
Klotho Neurosciences, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #629 of 976 |
Weight: Klotho Neurosciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Klotho Neurosciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Klotho Neurosciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KLTO by Market Capitalization
Companies near Klotho Neurosciences, Inc. in the global market cap rankings as of June 19, 2026.
Key companies related to Klotho Neurosciences, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Klotho Neurosciences, Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, Klotho Neurosciences, Inc.'s market cap moved from $1.09 Billion to $ 50.59 Million, with a yearly change of -54.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $50.59 Million | +61.94% |
| 2025 | $31.24 Million | -40.41% |
| 2024 | $52.42 Million | -95.47% |
| 2023 | $1.16 Billion | +6.31% |
| 2022 | $1.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Klotho Neurosciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.59 Million USD |
| MoneyControl | $50.59 Million USD |
| MarketWatch | $50.59 Million USD |
| marketcap.company | $50.59 Million USD |
| Reuters | $50.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more